513 related articles for article (PubMed ID: 19670459)
21. Relation of the degree of obesity in childhood to adipose tissue insulin resistance.
Hagman E; Besor O; Hershkop K; Santoro N; Pierpont B; Mata M; Caprio S; Weiss R
Acta Diabetol; 2019 Feb; 56(2):219-226. PubMed ID: 30637483
[TBL] [Abstract][Full Text] [Related]
22. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
Bajaj M; Suraamornkul S; Pratipanawatr T; Hardies LJ; Pratipanawatr W; Glass L; Cersosimo E; Miyazaki Y; DeFronzo RA
Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
[TBL] [Abstract][Full Text] [Related]
23. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Baig R; Suraamornkul S; Hardies LJ; Coletta DK; Cline GW; Monroy A; Koul S; Sriwijitkamol A; Musi N; Shulman GI; DeFronzo RA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1916-23. PubMed ID: 20157197
[TBL] [Abstract][Full Text] [Related]
24. Thiazolidinediones and the liver in humans.
Yki-Järvinen H
Curr Opin Lipidol; 2009 Dec; 20(6):477-83. PubMed ID: 19779336
[TBL] [Abstract][Full Text] [Related]
25. Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD.
Kalavalapalli S; Leiva EG; Lomonaco R; Chi X; Shrestha S; Dillard R; Budd J; Romero JP; Li C; Bril F; Samraj G; Pennington J; Townsend P; Orlando F; Shetty S; Mansour L; Silva-Sombra LR; Bedossa P; Malaty J; Barb D; Gurka MJ; Cusi K
J Clin Endocrinol Metab; 2023 Apr; 108(5):1192-1201. PubMed ID: 36378995
[TBL] [Abstract][Full Text] [Related]
26. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study.
Gastaldelli A; Gaggini M; Daniele G; Ciociaro D; Cersosimo E; Tripathy D; Triplitt C; Fox P; Musi N; DeFronzo R; Iozzo P
Hepatology; 2016 Dec; 64(6):2028-2037. PubMed ID: 27639082
[TBL] [Abstract][Full Text] [Related]
27. Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.
Zhang W; Wu R; Zhang F; Xu Y; Liu B; Yang Y; Zhou H; Wang L; Wan K; Xiao X; Zhang X
Clin Exp Pharmacol Physiol; 2012 Dec; 39(12):1026-33. PubMed ID: 23127227
[TBL] [Abstract][Full Text] [Related]
28. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes.
Albu JB; Heilbronn LK; Kelley DE; Smith SR; Azuma K; Berk ES; Pi-Sunyer FX; Ravussin E;
Diabetes; 2010 Mar; 59(3):627-33. PubMed ID: 20028945
[TBL] [Abstract][Full Text] [Related]
29. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.
Roden M; Mariz S; Brazzale AR; Pacini G
J Intern Med; 2009 Apr; 265(4):476-87. PubMed ID: 19298459
[TBL] [Abstract][Full Text] [Related]
30. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
Bril F; Kalavalapalli S; Clark VC; Lomonaco R; Soldevila-Pico C; Liu IC; Orsak B; Tio F; Cusi K
Clin Gastroenterol Hepatol; 2018 Apr; 16(4):558-566.e2. PubMed ID: 29223443
[TBL] [Abstract][Full Text] [Related]
31. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
[TBL] [Abstract][Full Text] [Related]
32. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
Miyazaki Y; Matsuda M; DeFronzo RA
Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
[TBL] [Abstract][Full Text] [Related]
33. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
[TBL] [Abstract][Full Text] [Related]
34. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone.
Leclercq IA; Lebrun VA; Stärkel P; Horsmans YJ
Lab Invest; 2007 Jan; 87(1):56-65. PubMed ID: 17075577
[TBL] [Abstract][Full Text] [Related]
35. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
[TBL] [Abstract][Full Text] [Related]
36. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients.
Bajaj M; Suraamornkul S; Hardies LJ; Pratipanawatr T; DeFronzo RA
Int J Obes Relat Metab Disord; 2004 Jun; 28(6):783-9. PubMed ID: 15024400
[TBL] [Abstract][Full Text] [Related]
37. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
38. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.
Ravikumar B; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
Diabetes; 2008 Sep; 57(9):2288-95. PubMed ID: 18535187
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).
Ortiz-Lopez C; Lomonaco R; Orsak B; Finch J; Chang Z; Kochunov VG; Hardies J; Cusi K
Diabetes Care; 2012 Apr; 35(4):873-8. PubMed ID: 22374640
[TBL] [Abstract][Full Text] [Related]
40. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.
Gastaldelli A; Casolaro A; Pettiti M; Nannipieri M; Ciociaro D; Frascerra S; Buzzigoli E; Baldi S; Mari A; Ferrannini E
Clin Pharmacol Ther; 2007 Feb; 81(2):205-12. PubMed ID: 17259945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
